122 related articles for article (PubMed ID: 36478247)
1. The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori.
Yang T; Liu B; Zhou J; Shen Y; Song X; Tang X; Benghezal M; Marshall BJ; Tang H; Li H
J Infect Dis; 2022 Dec; 226(Suppl 5):S479-S485. PubMed ID: 36478247
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of Helicobacter pylori resistance to rifamycins.
Hays C; Burucoa C; Lehours P; Tran CT; Leleu A; Raymond J
Helicobacter; 2018 Feb; 23(1):. PubMed ID: 29168600
[TBL] [Abstract][Full Text] [Related]
3. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany.
Glocker E; Bogdan C; Kist M
J Antimicrob Chemother; 2007 May; 59(5):874-9. PubMed ID: 17350989
[TBL] [Abstract][Full Text] [Related]
4. Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.
Lee Y; Kim SS; Choi SM; Bae CJ; Oh TH; Kim SE; Kim UJ; Kang SJ; Jung SI; Park KH
J Glob Antimicrob Resist; 2022 Mar; 28():43-48. PubMed ID: 34920175
[TBL] [Abstract][Full Text] [Related]
5. Rifamycin use for treatment of
Boyanova L; Markovska R; Hadzhiyski P; Kandilarov N; Mitov I
Future Microbiol; 2020 Aug; 15():1185-1196. PubMed ID: 32954842
[No Abstract] [Full Text] [Related]
6. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.
Suzuki S; Suzuki H; Nishizawa T; Kaneko F; Ootani S; Muraoka H; Saito Y; Kobayashi I; Hibi T
Digestion; 2009; 79(1):1-4. PubMed ID: 19142036
[TBL] [Abstract][Full Text] [Related]
7. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
Schön T; Juréen P; Chryssanthou E; Giske CG; Kahlmeter G; Hoffner S; Angeby K
J Antimicrob Chemother; 2013 Sep; 68(9):2074-7. PubMed ID: 23633684
[TBL] [Abstract][Full Text] [Related]
8. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
Rastogi N; Goh KS; Berchel M; Bryskier A
J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
[TBL] [Abstract][Full Text] [Related]
9. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.
Senol G; Erbaycu A; Ozsöz A
J Chemother; 2005 Aug; 17(4):380-4. PubMed ID: 16167516
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.
Farhat MR; Sixsmith J; Calderon R; Hicks ND; Fortune SM; Murray M
J Antimicrob Chemother; 2019 Jun; 74(6):1477-1483. PubMed ID: 30793747
[TBL] [Abstract][Full Text] [Related]
11. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan.
Kuo CJ; Bui NN; Ke JN; Lin CY; Lin WR; Chang ML; Wu HY; Huang MZ; Chiu CH; Chiu CT; Lai CH
Int J Infect Dis; 2024 Jan; 138():25-28. PubMed ID: 37956898
[TBL] [Abstract][Full Text] [Related]
13. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori.
Heep M; Lehn N; Brandstätter B; Rieger U; Senzenberger S; Wehrl W
Eur J Clin Microbiol Infect Dis; 2002 Feb; 21(2):143-5. PubMed ID: 11939398
[No Abstract] [Full Text] [Related]
14. Rifampin and rifabutin resistance mechanism in Helicobacter pylori.
Heep M; Beck D; Bayerdörffer E; Lehn N
Antimicrob Agents Chemother; 1999 Jun; 43(6):1497-9. PubMed ID: 10348780
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Cavusoglu C; Karaca-Derici Y; Bilgic A
Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
[TBL] [Abstract][Full Text] [Related]
17.
Albano M; Karau MJ; Greenwood-Quaintance KE; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451499
[TBL] [Abstract][Full Text] [Related]
18. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori.
Siavoshi F; Saniee P; Malekzadeh R
Helicobacter; 2018 Dec; 23(6):e12531. PubMed ID: 30230637
[TBL] [Abstract][Full Text] [Related]
19. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.
Abad L; Josse J; Tasse J; Lustig S; Ferry T; Diot A; Laurent F; Valour F
J Antimicrob Chemother; 2020 Jun; 75(6):1466-1473. PubMed ID: 32125419
[TBL] [Abstract][Full Text] [Related]
20. Whole-Genome Sequencing for Resistance Level Prediction in Multidrug-Resistant Tuberculosis.
Li J; Yang T; Hong C; Yang Z; Wu L; Gao Q; Yang H; Tan W
Microbiol Spectr; 2022 Jun; 10(3):e0271421. PubMed ID: 35658579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
